China Pharmaceutical Market Report 2011Pacific Bridge MedicalJanuary 1, 2011 38 Pages - SKU: PACB6382870 |
| Countries covered: China China's pharmaceutical market is a large, rising opportunity - reaching an estimated $38 billion in 2009 and still growing at almost 20% annually. By 2012, China should rank as the world’s third largest pharmaceutical market and is expected to grow to $100 billion by 2015. This makes it strategically crucial for Western pharmaceutical companies to succeed in China. However, the Chinese pharmaceutical market has unique characteristics which must be understood to make the China potential a reality. This research report contains key information on multiple important topics of the Chinese pharmaceutical market, including market data, the role of government health insurance reimbursement, government price controls, institutional purchasing practices, differing characteristics and business strategies of domestic and foreign pharmaceutical companies, and more. It also includes three appendices: one on recent acquisitions, ventures, and partnerships in the Chinese drug industry; a list of all drugs which Chinese government health insurance will reimburse; and contact information for key Chinese drug agencies. |
More China Regulation & Policy Reports
China’s Guidebook for Pharmaceutical Patent Protection by
Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...
China Chinese Patent Drug Processing Industry, 2012 by
Reports From China
China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese ...
China Drug Patent Inventor Report - 2011 Publication List by
DrugPatentWatch
TheChina Drug Patent Inventor Reportprofiles China-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...
China Pharmaceutical Equipment Industry Report, 2011-2012 by
Research in China
In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales ...
Healthcare Reform in China by
Business Insights
China's pharmaceutical market is growing rapidly in step with it's wider economy. The government aims to extend healthcare coverage to it's 1.3bn citizens, which will ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by
MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>
Related Markets
Regulation & Policy Reports
- Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs
- Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
